Longeveron (LGVN) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 12, 2022 8:00 AM EDTLongeverons Phase 2a trial of Lomecel-B for patients with mild Alzheimers Disease proceeding on schedule, currently at 50% enrollment
Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin
Top-line findings from the second phase of the Phase 1/2 HERA trial show that the primary endpoint for safety was met in the randomized placebo-controlled portion of the study
$27 million in cash, cash equivalents and short-term investments as of June 30, 2022, expected to be sufficient to fund operations into 2024
... More